Cara Therapeutics is an early commercial-stage biopharmaceutical company leading a new treatment to improve the lives of patients suffering from pruritus. The company’s novel KORSUVA™ (difelikefalin) injection is the first and only FDA-approved treatment for moderate-to-severe pruritus associated with chronic kidney disease in adults undergoing hemodialysis. The company is developing an oral formulation of difelikefalin for the treatment of pruritus in patients with non-dialysis dependent advanced chronic kidney disease, atopic dermatitis, and notalgia paresthetica.
